Infections with H5/H7 low-pathogenic avian influenza (LPAI) viruses are now notifiable because such viruses can mutate into highly pathogenic avian influenza viruses, leading to serious problems for both animal and public health. Domestic ducks can play a crucial role in the transmission of H5 LPAI viruses to other poultry. Although prime boost vaccination using, respectively, a recombinant vaccine and an inactivated vaccine was shown to be protective in ducks against H5N1 highly pathogenic avian influenza, vaccination of domestic ducks against H5 LPAIV is poorly documented. However, substituting inactivated vaccines with subunit vaccines might be more advantageous. In this context, we generated a triple recombinant baculovirus composed of HA and NA proteins derived from a French H5N3 LPAI virus strain and the M protein derived from an Italian H7N1 LPAI virus strain. We describe a molecular construction strategy that enabled the development of virus-like particles (VLPs). Western blot analyses and neuraminidase inhibition assay of cell supernatants purified by sucrose density gradient ultracentrifugation showed that HA, NA and M1 proteins were expressed and co-released. Electron microscopy examination revealed VLPs that were morphologically identical to wild-type virus. Immunogold electron microscopy demonstrated that H5 and N3 proteins were present on the VLP surface, and haemagglutination and neuraminidase assays showed that the H and N proteins, respectively, were biologically active. In addition, VLP immunogenicity (induction of haemagglutination-inhibiting antibodies) was demonstrated in specific pathogen free Muscovy ducks. According to our successful previous experimental results of protection in ducks following vaccination with the three baculovirus-expressed proteins, the present results make feasible the reliable use of H5N3 VLPs as a subunit vaccine in this species.
In Asia, domestic ducks have been shown to play a pivotal role in H5 high-pathogenicity avian influenza virus transmission. We have also observed that the same situation may exist for H5 low-pathogenicity avian influenza (LPAI) virus. No data are available regarding the protection afforded by commercial inactivated vaccines against H5 LPAI virus infection in ducks, and two preliminary experiments using commercial inactivated vaccines gave poor results. Virus-like particles (VLPs) have been shown to be immunogenic in different species. With regard to the influenza model, the matrix (M) protein has been shown to be necessary for the formation of VLPs. In order to attempt to develop a VLP influenza vaccine expressing hemagglutinin and neuraminidase (NA) of interest, we generated a triple recombinant baculovirus (rB) expressing three structural proteins: H5, N3, and M, derived from a recent French LPAI virus strain. Although the three proteins were successfully expressed in rB-infected cells and displayed the expected biological activity, no VLPs were observed. Despite this result, the protection afforded to ducks by rB-infected cell lysates was assessed and was compared with the protection afforded by an inactivated commercial H5N9 vaccine. For this purpose, specific-pathogen-free Muscovy ducks (15 per group) received rB-infected cell lysates (3 wk apart), while a second group received the H5N9 vaccine. Ten days after the boost, a homologous virus challenge was implemented. Both vaccines induced positive hemagglutination inhibition titers and M immune response, whereas lysates of rB-infected cells elicited NA immune response. Tracheal and cloacal sheddings were measured using M-based real-time-reverse transcription-polymerase chain reaction and were compared with the sheddings of vaccinated and unvaccinated infected controls. Lysates of rB-infected cells afforded a significant decrease of cloacal shedding and a delayed peak of tracheal shedding, whereas the inactivated commercial vaccine afforded a significant decrease of tracheal shedding only.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.